CardioVascular and Interventional Radiology

, Volume 41, Issue 6, pp 912–919 | Cite as

Does the Site of the Primary Affect Outcomes When Ablating Colorectal Liver Metastases with Radiofrequency Ablation?

  • Yangkui Gu
  • Zhimei Huang
  • Haifeng Gu
  • Fei Gao
  • Tianqi Zhang
  • Senmiao Huang
  • Jinhua Huang
Clinical Investigation



To determine whether primary tumor side was a predictor of radiofrequency ablation (RFA) outcome in colorectal liver metastases (CRLM).

Materials and Methods

The institutional review board approved this retrospective study. Written informed consent was obtained from all patients. From January 2007 to December 2013, 102 patients underwent RFA of metachronous CRLM were enrolled in this study with propensity score matching method. Recurrence rate (RR) and overall survival (OS) were analyzed between two patients cohorts with primary left-side colorectal cancer (LSCRC) or primary right-side colon cancer (RSCC).


The total RR was 59.8% in all patients. Patients in LSCRC cohort had lower RR and non-local recurrence (NLR) rate than those in RSCC patients’ cohort (49.0 vs 70.6%, p = 0.026 and 21.6 vs 41.2%, p = 0.033). Five-year OS was 14 and 30% for RSCC and LSCRC, respectively. There was a significant difference between two cohorts in median OS (29.4 vs 40.3 months for RSCC and LSCRC, respectively, p = 0.042). Univariate analysis showed that primary tumor side, the number of liver metastases, tumor size, carcinoembryonic antigen level, differentiation, TNM stage, active chemotherapy and RFA boundary were significant in predicting OS. When these variables were subsequently entered in a multivariate model, RSCC (p < 0.001; hazard ratio [HR], 6.2) and tumor size (> 3 cm) (p = 0.006; HR, 3.9) were significant.


LSCRC and tumor size (≤ 3 cm) are independent predictors of RFA in CRLM and yield the better oncologic outcomes.


Colorectal Liver metastases Radiofrequency ablation Tumor side Outcome 



This work was supported by National Natural Science Foundation of China (No. 81371652), Guangzhou Science and Technology Program, key projects of collaborative innovation of health medicine (No. 201704020228), and Guangzhou Science and Technology Program, key projects of collaborative innovation of production, learning and research (No. 201704020134).

Compliance with Ethical Standards

Conflict of interest

There are no actual or potential conflicts of interest.


  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.CrossRefPubMedGoogle Scholar
  2. 2.
    Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18 discussion 18–21.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Are C, Gonen M, Zazzali K, et al. The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg. 2007;246(2):295–300.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Abdalla EK, Adam R, Bilchik AJ, Jaeck D, Vauthey JN, Mahvi D. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271–80.CrossRefPubMedGoogle Scholar
  5. 5.
    Muratore A, Ribero D, Zimmitti G, Mellano A, Langella S, Capussotti L. Resection margin and recurrence-free survival after liver resection of colorectal metastases. Ann Surg Oncol. 2010;17(5):1324–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27(22):3677–83.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mayo SC, Pawlik TM. Thermal ablative therapies for secondary hepatic malignancies. Cancer J. 2010;16(2):111–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Gillams AR. Liver ablation therapy. Br J Radiol. 2004;77(921):713–23.CrossRefPubMedGoogle Scholar
  9. 9.
    Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol. 2009;19(5):1206–13.CrossRefPubMedGoogle Scholar
  10. 10.
    Van Tilborg AA, Meijerink MR, Sietses C, et al. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol. 1002;2011(84):556–65.Google Scholar
  11. 11.
    Hamada A, Yamakado K, Nakatsuka A, et al. Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates. Jpn J Radiol. 2012;30(7):567–74.CrossRefPubMedGoogle Scholar
  12. 12.
    Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23(10):2619–26.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Benedix F, Kube R, Meyer F, et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53(1):57–64.CrossRefPubMedGoogle Scholar
  14. 14.
    Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: pathologic aspects. J Gastrointest Oncol. 2012;3(3):153–73.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Nawa T, Kato J, Kawamoto H, et al. Differences between right- and left-sided colon cancer in patient characteristics, cancer morphology and histology. J Gastroenterol Hepatol. 2008;23(3):418–23.CrossRefPubMedGoogle Scholar
  16. 16.
    Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right-versus left-sided colon cancers? Ann Surg Oncol. 2008;15(9):2388–94.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kuramochi H, Nakamura A, Nakajima G, et al. PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational study. BMC Cancer. 2016;16:366.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Shady W, Petre EN, Gonen M, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes—a 10-year experience at a single center. Radiology. 2016;278(2):601–11.CrossRefPubMedGoogle Scholar
  19. 19.
    Mulier S, Mulier P, Ni Y, et al. Complications of radiofrequency coagulation of liver tumours. Br J Surg. 2002;89(10):1206–22.CrossRefPubMedGoogle Scholar
  20. 20.
    Curley SA, Marra P, Beaty K, et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg. 2004;239(4):450–8.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Elias D, Baton O, Sideris L, et al. Hepatectomy plus intraoperative radiofrequency ablation and chemotherapy to treat technically unresectable multiple colorectal liver metastases. J Surg Oncol. 2005;90(1):36–42.CrossRefPubMedGoogle Scholar
  22. 22.
    Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242(2):158–71.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Veltri A, Guarnieri T, Gazzera C, et al. Long-term outcome of radiofrequency thermal ablation (RFA) of liver metastases from colorectal cancer (CRC): size as the leading prognostic factor for survival. Radiol Med. 2012;117(7):1139–51.CrossRefPubMedGoogle Scholar
  24. 24.
    Yamashita S, Brudvik KW, Kopetz SE, et al. Embryonic origin of primary colon cancer predicts pathologic response and survival in patients undergoing resection for colon cancer liver metastases. Ann Surg. 2018;267(3):514–20.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Creasy JM, Sadot E, Koerkamp BG, et al. The impact of primary tumor location on long-term survival in patients undergoing hepatic resection for metastatic colon cancer. Ann Surg Oncol. 2018;25(2):431–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113(10):779–88.CrossRefPubMedGoogle Scholar
  27. 27.
    Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol. 2004;88(4):261–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Pocard M, Salmon RJ, Muleris M, et al. Two colons–two cancers? Proximal or distal adenocarcinoma: arguments for a different carcinogenesis. Bull Cancer. 1995;82(1):10–21.PubMedGoogle Scholar
  29. 29.
    Zhang Y, Ma J, Zhang S, et al. A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. Int J Colorectal Dis. 2015;30(9):1173–83.CrossRefPubMedGoogle Scholar
  30. 30.
    Yamauchi M, Morikawa T, Kuchiba A, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61(6):847–54.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Dhir M, Lyden ER, Smith LM, Are C. Influence of margins on disease free survival following hepatic resection for colorectal metastasis: a meta-analysis. Indian J Surg Oncol. 2012;3(4):321–9.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Xu J, Zhong Y, Weixin N, et al. Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. Ann Surg. 2007;245(4):583–90.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Kemeny NE, Chou JF, Boucher TM, et al. Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. J Surg Oncol. 2016;113(5):477–84.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Koerkamp BG, Sadot E, Kemeny NE, et al. Perioperative hepatic arterial infusion pump chemotherapy is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis. J Clin Oncol. 2017;35(17):1938–44.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2018

Authors and Affiliations

  1. 1.Department of Minimally Invasive Interventional Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouPeople’s Republic of China
  2. 2.Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouPeople’s Republic of China
  3. 3.Department of OncologyPanyu Central HospitalGuangzhouPeople’s Republic of China

Personalised recommendations